Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non–vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH–AFNET 6) trial

Paulus Kirchhof, MD, a,b,c,d Benjamin F. Blank, d Melanie Calvert, PhD, e,f A. John Camm, MD, g Gregory Chlouverakis, PhD, h Hans-Christoph Diener, MD, i Andreas Goette, MD, j,k Andrea Huening, MD, k Gregory Y. H. Lip, MD, a,b,l Emmanuel Simantirakis, MD, m and Panos Vardas, MD m

Background Oral anticoagulation prevents ischemic strokes in patients with atrial fibrillation (AF). Early detection of AF and subsequent initiation of oral anticoagulation help to prevent strokes in AF patients. Implanted cardiac pacemakers and defibrillators allow seamless detection of atrial high rate episodes (AHRE), but the best antithrombotic therapy in patients with AHRE is not known.

Rationale Stroke risk is higher in pacemaker patients with AHRE than in those without, but the available data also show that stroke risk in patients with AHRE is lower than in patients with AF. Furthermore, only a minority of patients with AHRE will develop AF, many strokes occur without a temporal relation to AHRE, and AHRE can reflect other arrhythmias than AF or artifacts. An adequately powered controlled trial of oral anticoagulation in patients with AHRE is needed.

Design The Non–vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH–AFNET 6) trial tests whether oral anticoagulation with edoxaban is superior to prevent the primary efficacy outcome of stroke or cardiovascular death compared with aspirin or no antithrombotic therapy based on evidence-based indications. The primary safety outcome will be major bleeding. NOAH–AFNET 6 will randomize 3,400 patients with AHRE, but without documented AF, aged ≥65 years with at least 1 other stroke risk factor, to oral anticoagulation therapy (edoxaban) or no anticoagulation. All patients will be followed until the end of this investigator-driven, prospective, parallel-group, randomized, event-driven, double-blind, multicenter phase IIIb trial. Patients will be censored when they develop AF and offered open-label anticoagulation. The sponsor is the Atrial Fibrillation NETwork (AFNET). The trial is supported by the DZHK (German Centre for Cardiovascular Research), the BMBF (German Ministry of Education and Research), and Daiichi Sankyo Europe.

Conclusion NOAH–AFNET 6 will provide robust information on the effect of oral anticoagulation in patients with atrial high rate episodes detected by implanted devices. (Am Heart J 2017;190:12-18.)
stroke prevention efficacy and are at least as safe as VKA, with less intracranial hemorrhage and a 10% reduction in mortality in the pivotal trials. So far, all available data that demonstrate a beneficial effect of oral anticoagulation for stroke prevention have been collected in populations with AF documented by conventional electrocardiogram (ECG). Studies in other populations in the absence of AF, for example, heart failure or survivors of a stroke, had overall neutral outcomes, where slight reductions in stroke were counterbalanced by increased bleeding. Therefore, antiplatelet therapy is recommended for secondary prevention of ischemic strokes in patients without AF or other cardioembolic cause of stroke.

Many AF episodes remain undiagnosed. Often, a potentially preventable stroke is the first clinical manifestation of hitherto undetected AF (silent AF). In fact, around 5% of unselected patients presenting with an acute stroke suffer from silent AF that is detected by a simple ECG upon admission. Published and ongoing studies suggest that systematic ECG screening using patient-operated devices or ‘opportunistic screening’ in those presenting to a health care professional can detect silent AF. This is in line with predictions made from trial data sets. Systematic ECG monitoring in stroke survivors detects silent paroxysmal AF in approximately 5% of unselected stroke patients and in up to 20% when long-term ECG monitoring is applied to patients with cryptogenic stroke. Even these prolonged ECG monitoring techniques will miss silent AF in many patients. Continuous monitoring of atrial rhythm could close this diagnostic gap, requiring implanted devices and automated or semiautomated analysis. Most modern pacemakers, defibrillators, and cardiac resynchronization devices provide automated algorithms alerting to the occurrence of atrial high rate episodes, also called subclinical atrial fibrillation or, more appropriately, device-detected atrial high rate episodes (AHRE). Data from large prospectively followed patient cohorts have demonstrated that the presence of AHRE increases stroke risk. Only a minority of patients with AHRE (estimated at 13%-16% over 2.5 years) will develop AF. The absolute stroke rates are lower in patients with AHRE when compared with stroke rates in patients with clinically diagnosed AF. For example, the TRENDS cohort, collecting information on patients with long AHRE episodes, reported a stroke rate of 1.1%-2.2% per year. One of the largest cohorts, SOS, reported AHRE and stroke rates in >10,000 unselected device patients (mean age 70 years, more than 50% with additional stroke risk factors, 80% not anticoagulated). AHRE were found in 43% of all patients. The annual rate of stroke or transient ischemic attack was between 0.32% and 0.67% per year. Stroke rates of around 1.7% per year were reported in patients with AHRE enrolled into the ASSERT and IMPACT trials. Higher stroke rates were reported in other smaller and earlier series (Table II). The SOS data set did not show a clear increase in patients with higher AHRE burden (Figure 3 in Boriani et al). Other analyses in smaller populations have suggested that longer AHRE episodes (eg, those lasting >24 hours) are associated with a higher stroke risk. Furthermore, automated detection algorithms of AHRE by implanted devices have a good sensitivity, but their specificity may not be optimal, especially for short episodes, to constantly distinguish AF from other arrhythmias or artifacts. As an illustrative example, 15% (19/130) patients without AF on a simultaneously recorded Holter ECG were classified as having AF on an implanted loop recorder. In summary, stroke rates in patients with AHRE are often close to the threshold for a net clinical benefit of NOAC therapy and appear lower than the stroke rates found in patients with paroxysmal AF detected by ECG.

Also, only a minority of ischemic strokes in pacemaker patients with AHRE occur in relation to the time of an AHRE episode. In light of the bleeding complications associated with oral anticoagulation, patients with AHRE should currently only be anticoagulated once AF has been documented by ECG, a resource-intensive and time-consuming process. A sufficiently powered randomized trial of continuous oral anticoagulation compared with no anticoagulation in 2,718 AHRE patients. In light of the bleeding complications associated with oral anticoagulation, patients with AHRE may be at risk of nonvalvular atrial fibrillation or atrial flutter, and they should be considered for therapy with NOACs. Patients with AHRE may be at higher risk of stroke, and the use of NOACs may be appropriate. There is also a potential role for NOACs in patients with AHRE who are at high risk of stroke, such as those with a history of stroke or transient ischemic attack. Further studies are needed to determine the optimal management of patients with AHRE.
Design of the Non–vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes trial

**Hypothesis.** The Non–vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH–AFNET 6) trial tests the hypothesis that oral anticoagulation with the NOAC edoxaban is superior to current therapy (antiplatelet therapy or no therapy depending on cardiovascular risk) to prevent stroke, systemic embolism, or cardiovascular death in patients with AHRE, but without AF, and with at least 2 stroke risk factors. We will also assess whether the intervention improves quality of life and maintains cognitive function.

NOAH–AFNET 6 is registered at clinicaltrials.gov (NCT026218577), EudraCT (2015-003997-33), and ISRCTN (17309850). The protocol was developed in accordance with the Standard Protocol Items for Randomized Trials statement and guidance from the International Society for Quality of Life Research Best Practice task force. No funding other than the sources mentioned in the acknowledgment was used to support this work. The authors and the study sponsor, AFNET, are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper, and its final contents. Further information can be obtained from the trial Web site: www.noah.af-net.eu.

**Patient population**

NOAH–AFNET 6 will enroll patients with AHRE but without diagnosed AF or another accepted indication for oral anticoagulation. Patients in the trial who would qualify for oral anticoagulation if they had diagnosed AF, approximated by an age of 65 years or more and presence of at least 1 additional clinical stroke risk factor. The trial has broad inclusion and exclusion criteria in line with a simple trial that is close to clinical practice (see Table I for details). It has been reported that approximately 1 of 7 (13%-16%) of patients with device-detected AHRE will develop AF over a mean follow-up of 2.5 years. Patients will undergo ECG in 6-month intervals (at baseline and during follow-up). Patients will be censored at the time of developing AF and taken off study medication, as they have an indication for oral anticoagulation. All patients will be followed up until the end of the trial. To date, 118 sites have been initiated in 11 countries. One hundred thirty-one patients have been randomized so far.

**Trial organization**

NOAH–AFNET 6 is an investigator-initiated, prospective, parallel-group, double-blind, randomized, multicenter phase IIIb trial (Figure). Study patients will be randomized to 1 of 2 parallel groups in a 1:1 design, designated as NOAC and Usual Care. Randomization will be stratified by indication for use of antiplatelet therapy as assessed by the responsible site investigator at the time of randomization. Patients randomized to the NOAC group will receive edoxaban in the therapeutic dose approved for stroke prevention in AF, that is, 60 mg od with a reduction of dose to 30 mg od in patients with impaired renal function, low body weight, or receiving certain glycoprotein P inhibitors. Patients randomized to usual care will receive either placebo or aspirin depending on established indications for aspirin therapy. NOAH–AFNET 6 is a joint project of the Atrial Fibrillation NETwork (AFNET) and of the European Society of Cardiology. AFNET is sponsor of the trial. The study is led by an academic steering committee and overseen by a data safety and monitoring board. The trial will be conducted with the help of a clinical research organization, the Clinical Research Institute based in Munich.

NOAH–AFNET 6 is supported by Daiichi Sankyo Europe; the DZHK (German Centre for Cardiovascular Research); and the BMBF (German Ministry of Education and Research, FKZ 81x2800110).

**Outcome parameters.** The primary outcome parameter of NOAH–AFNET 6 is a composite of stroke, systemic embolism, or cardiovascular death, measured as the time from randomization to the first occurrence of either of these events. All events will be centrally adjudicated by an independent committee. Secondary outcome parameters include components of the primary outcome, all-cause death, major bleeding events according to the ISTH definitions, changes in quality of life assessed using the EQ-5D and the Karnofsky scale, patient satisfaction assessed by the modified European Heart Rhythm Association Symptoms (mEHRA) score and PACT-Q, and cognitive function assessed by the Montreal Cognitive Assessment (MoCA) at 12 and 24 months compared with baseline. Cost-effectiveness and health resource utilization will be assessed. All AHRE episodes will be reanalyzed by an independent core laboratory based at Maastricht University to verify whether AHRE data uploaded by trial sites fulfill the requirements of the protocol as inclusion criteria. The core laboratory also performs quality control and provides feedback to trial sites regarding their uploaded AHRE data if necessary. Prespecified exploratory analyses will include markers identifying patients at high stroke risk, for example, by duration or pattern of AHRE episodes, or using blood/ECG analyses. All patients will be followed up until the end of the trial.

**Estimation of the event rate and effect size for the primary outcome in the NOAH–AFNET 6 population.** To arrive at a reliable estimate of the control group event rate in the NOAH–AFNET 6 patient population, stroke/systemic embolism and cardiovascular death rates in patients with AHRE in published series were compiled (Table II). Based on this analysis, considering stroke and death rates in nonanticoagulated patients with paroxysmal AF and accounting for the variability in stroke rate estimates in published series of patients with AHRE (Table II), an annual stroke rate of 1.9% and an annual cardiovascular
### Table 1. Inclusion and exclusion criteria of the NOAH–AFNET 6 trial

| Inclusion criteria                                                                 | Exclusion criteria                                                                 |
|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| I1. Pacemaker or defibrillator implanted for any reason with feature              | E1. Any disease that limits life expectancy to less than 1 y                        |
| of detection of AHRE, implanted at least 2 m prior to randomization               | E2. Participation in another controlled clinical trial, either within the           |
| I2. AHRE detection feature activated                                              | past 2 months or still ongoing                                                     |
| I3. AHRE (≥ 180 beats/min atrial rate and ≥ 6-min duration) documented by the    | E3. Previous participation in the present trial NOAH–AFNET 6                       |
| implanted device via its atrial lead and stored digitally                          |                                                                                     |
| I4. Age ≥ 65 y                                                                    | E4. Drug abuse or clinically manifest alcohol abuse                                |
| I5. In addition, at least 1 of the following cardiovascular conditions            | E5. Any history of AF or atrial flutter or presence of AF at baseline 12-lead ECG   |
|   - Age ≥ 75 y                                                                    |                                                                                     |
|   - Heart failure (clinically overt or LVEF < 45%),                               |                                                                                     |
|   - Arterial hypertension (long-term treatment for hypertension, estimated      |                                                                                     |
|     need for continuous antihypertensive therapy, or resting blood pressure > 145/90 mm Hg, |                                                                                     |
|   - Diabetes mellitus,                                                            |                                                                                     |
|   - Prior stroke or TIA, or                                                       |                                                                                     |
|   - Vascular disease (peripheral, carotid/cerebral, or aortic plaques on TEE).   |                                                                                     |
| I6. Provision of signed informed consent                                            |                                                                                     |

The inclusion criteria I4 and I5 closely resemble the criteria of a CHA2DS2-VASc score of ≥ 2 in patients with diagnosed AF. Patients with a transient requirement for dual antiplatelet therapy (DAPT, eg, after receiving a stent) will be eligible when the need for DAPT is no longer present.

The potential benefit of oral anticoagulation in the NOAH–AFNET 6 population will have to be weighed against the bleeding risk associated with long-term NOAC therapy (Table III). It is worthwhile to note the IMPACT trial in this context: IMPACT did not find a benefit of intermittent anticoagulation, initiated at the time of device-detected AHRE and continued for 30 to 90 days after documentation of the last AHRE event, to usual care (no anticoagulation) in 2,718 patients with AHRE and a median CHA2DS2-VASc score of 4. IMPACT observed 22 ischemic strokes and 41 major bleeding events, illustrating the equipoise for anticoagulation in patients with device-detected AHRE and stroke risk factors.

**Sample size.** Three thousand four hundred patients will be randomized. Computation of sample size is based on a hazard ratio of 0.68, accrual period of 27 months, and minimum follow-up of 12 months. Specifically, it assumes annual hazard rates of 5.3% for the standard treatment group versus 3.62% for the NOAC group. This is equivalent to median event-free survival of 13 years for the standard treatment group versus 19 years for the NOAC group. This effect size is considered realistic in view of the effect of continuous oral anticoagulation in patients with AF. The minimum number of events that need to be observed to detect the aforementioned death rate of 3.3% are expected, or a rate of the primary outcome of 5.3% per year. For the purpose of NOAH–AFNET 6, patients randomized to edoxaban are expected to have a two-thirds lower rate of stroke or TIA and a 10% reduction in cardiovascular death. The effect estimate for stroke prevention is based on the effect size observed for stroke prevention with VKA (warfarin) or a NOAC (apixaban) compared with acetylsalicylic acid in patients with AF, assuming that edoxaban is at least as effective as dose-adjusted warfarin in preventing strokes in AHRE patients. The effect size for reduction in cardiovascular death is the point estimate of reduction in cardiovascular deaths observed in the 4 NOAC trials compared with warfarin. This conservative estimate is based on the assumption that the mortality benefit of edoxaban compared with no anticoagulation in NOAH-AFNET 6 is not bigger than the mortality benefit of edoxaban compared with dose-adjusted warfarin observed in ENGAGE-TIMI 48 and in the other 3 NOAC trials. These assumptions result in an estimated event rate of 0.62% per year for stroke and 3% for cardiovascular death. The expected event rate in the edoxaban group in NOAH-AFNET 6 (3.62% per year) is very similar to the observed rate of stroke or cardiovascular death in those patients enrolled in ENGAGE and randomized to edoxaban who match the NOAH-AFNET 6 inclusion criteria (3.45% per year, data on file).
difference as significant at the 2-sided 5% level, with 80%

power, is 222. Given the accrual and follow-up periods, at

least 1,260 patients per group are needed for that number

of events during the trial duration. The hazard of
developing overt AF or of dropping out of the trial for

other reasons is assumed to be at 0.287 throughout the

trial, equivalent to 25% of patients being censored in the

first year and rising to 57% at the end of 3 years. This

number includes patients who will develop AF, for

example, detected by routine ECG during follow-up visits

or by ECG monitoring initiated at the study sites. Taking

this into account, the number of patients per group

increases to 1,700. To account for slight variation of trial

duration and variability between estimated and observed

event rates, the trial protocol includes an interim analysis

of the combined enrolment and event rates (blind to

random group), with the possibility to adapt sample size.

**Conclusion**

In summary, the optimal antithrombotic therapy in

patients with AHRE but without diagnosed AF cannot be
derived from existing data. The information gained from

NOAH–AFNET 6 and from the ARTESia trial (NCT01938248)

will provide sound evidence to guide the use of oral

anticoagulation in patients with device-detected AHRE and

possibly in patients with atrial arrhythmias documented by

other devices. The results have the potential to inform future

guidance on the management of patients with atrial

arrhythmias detected by implantable devices.

---

### Table II. Annualized rate of stroke and cardiovascular death in patients with device-detected AHRE

| Study/population | Stroke | Cardiovascular death | Sum  |
|------------------|--------|----------------------|------|
| ASSERT,24 261 pts, 2.5-y FU | 1.7    | 2.9                  | 4.5  |
| MOST,25 160 pts, 2.25-y FU | 5      | 4.2                  | 9.2  |
| AT500,26 725 pts, 1.8-y FU | 3.6    |                      |      |
| Botto et al,26 223 pts, 1-y FU | 3.2    |                      |      |
| TRENDS,30 1.4-y FU | 1.2    |                      |      |
| SOS,27 10,106 pts, 2.2-y FU* | 0.4-0.8 |                      |      |

Event rates are given as percentage per year, split by stroke and cardiovascular death.
The sum of these 2 components provides a first estimate of the primary outcome rate.
All events are rounded to 1 decimal percentage point.
The table lists event rates that were available at the time of designing NOAH–AFNET 6.
* SOS included approximately 20% of anticoagulated patients. Death and bleeding
event rates are not reported.
† MOST, TRENDS, and AT500 included patients with atrial fibrillation diagnosed by
ECG, thereby probably enriching for patients at higher stroke risk.
References

1. Kirchhof P, Curtis AB, Skanes AC, et al. Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiovascular Surgery, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society. Eur Heart J 2013;34(20):1471-4.

2. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37(38):2893-962.

3. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014;130(23):e199-267.

4. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365(10):883-91.

5. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139-51.

6. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369(22):2093-104.

7. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(11):981-92.

8. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883-91.

9. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369(22):2093-104.

10. Goette A, Merino JL, Ezekowitz MD, et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 2016;388(10055):1995-2003.

11. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383(9921):955-62.

12. Homma S, Thompson JL, Pullicino PM, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012;366(20):1859-69.

13. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345(20):1444-51.

14. Jabbour D, Szatzeil J, Sievert K, et al. Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischemic attack. Stroke 2004;35(7):1647-51.

15. Samol A, Masin M, Gellner P, et al. Prevalence of unknown atrial fibrillation in patients with risk factors. Europace 2013;15(5):657-62.

16. Engdahl J, Andersson L, Mirskaya M, et al. Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention. Circulation 2013;127(8):930-7.

17. Svennberg E, Engdahl J, Al-Khalili F, et al. Mass screening for untreated atrial fibrillation: the STROKESTOP study. Circulation 2015;131(25):2176-84.

18. Fitzmaurice DA, Hobbs FD, Jowett S, et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ 2007;335(7616):383.

19. Kirchhof P, Bax J, Blomström-Lundqvist C, et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference. Research perspectives in AF. Eur Heart J 2009;30(24):2969-77c.

20. Rizos T, Gunter J, Jenetzky E, et al. Continuous stroke unit electrocardiographic monitoring versus 24-hour Holter electrocardiography for detection of paroxysmal atrial fibrillation after stroke. Stroke 2012;43(10):2689-94.

21. Ritter MA, Kochhauser S, Duning T, et al. Occult atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014;370(26):2478-86.

22. Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014;370(26):2478-86.

23. Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014;370(26):2467-77.

24. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012;366(2):120-9.

25. Kirchhof P, Lip GY, Van Gelder IC, et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options—a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. European 2012;14(1):8-27.

26. Glotzer TV, Hellkamp AS, Zimmerman J, et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Arrhythmias Ancillary Study of the MOde Selection Trial (MOST). Circulation 2003;107(12):1614-9.

27. Boriani G, Glotzer TV, Santini M, et al. Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke preventOn Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J 2014;35(8):508-16.

28. Israel CW, Ehrlich JR, Gronefeld G, et al. Prevalence, characteristics and clinical implications of regular atrial tachyarrhythmias in patients

Table III. Comparison of published annualized ischemic and bleeding event rates in populations with diagnosed AF that otherwise resemble the projected NOAH–AFNET 6 population

| Study | Stroke, systemic embolism, or cardiovascular death | Fatal bleeding | Hemorrhagic stroke plus other intracranial hemorrhage | Major extracranial hemorrhage |
|-------|-----------------------------------------------|----------------|--------------------------------------------------------|-----------------------------|
| ENGAGE-TIMI 48 edoxaban 60 mg od dosing regime 8 | 3.85 | 0.20 | 0.39 | 2.65 |
| AVERROES aspirin arm 5 | 6.40 | 0.20 | 0.50 | 1.2* |
| BAFTA aspirin 36 | 8.10 | 0.20 | 0.50 | 2.00 |

The chart shows major efficacy (stroke or cardiovascular death, red) and safety events (fatal bleeding, hemorrhagic stroke or intracranial hemorrhage, major extracranial bleeding) in controlled trials comparing anticoagulation with aspirin and in the ENGAGE-TIMI 48 trial evaluating edoxaban.

* For the AVERROES acetylsalicylic acid group, only the AVERROES major bleeds are reported, although some of the “clinically relevant nonmajor bleeds” in AVERROES would have been classified as “major” in BAFTA and ENGAGE.
with atrial fibrillation: insights from a study using a new implantable device. J Am Coll Cardiol 2001;38(2):355-63.
29. Swiryn S, Orlov MV, Benditt DG, et al. Clinical implications of brief device-detected atrial tachyarrhythmias in a cardiac rhythm management device population: results from the registry of atrial tachycardia and atrial fibrillation episodes. Circulation 2016;134(16):1130-40.
30. Glotzer TV, Daoud EG, Wyse DG, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol 2009;2(5):474-80.
31. Martin DT, Bersohn MM, Waldo AL, et al. Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. Eur Heart J 2015;36(26):1660-8.
32. Witt CT, Kronborg MB, Nohr EA, et al. Early detection of atrial high rate episodes predicts atrial fibrillation and thromboembolic events in patients with cardiac resynchronization therapy. Heart Rhythm 2015;12(12):2368-75.
33. Van Gelder IC, Healey JS, Crijns HJ, et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J 2015;36(26):1660-8.
34. Van Gelder IC, Healey JS, Crijns HJ, et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J 2015;36(26):1660-8.
35. Kaufman ES, Israel CW, Nair GM, et al. Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: an analysis from ASSERT. Heart Rhythm 2012;9(8):1341-6.
36. Van Gelder IC, Healey JS, Crijns HJ, et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J 2015;36(26):1660-8.
37. Vanassche T, Lauw MN, Eikelboom JW, et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J 2015;36(5):281-7a.
38. Ziegler PD, Glotzer TV, Daoud EG, et al. Incidence of newly detected atrial arrhythmias via implantable devices in patients with a history of thromboembolic events. Stroke 2010;41(2):256-60.
39. Daoud EG, Glotzer TV, Wyse DG, et al. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS. Heart Rhythm 2011;8(9):1416-23.
40. Brambatti M, Connolly SJ, Gold MR, et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation 2014;129(21):2094-9.
41. Passman R, Leong-Sit P, Andrei AC, et al. Targeted anticoagulation for atrial fibrillation guided by continuous rhythm assessment with an insertable cardiac monitor: the Rhythm Evaluation for Anticoagulation with Continuous Monitoring (REACT.COM) pilot study. J Cardiovasc Electrophysiol 2016;27(3):264-70.
42. Camm AJ, Amarenco P, Haas S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016;37(14):1145-53.
43. Bassand JP, Accetta G, Camm AJ, et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J 2016.
44. Graham DJ, Reichman ME, Wernke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015;131(2):157-64.
45. Larsen TB, Skjøth F, Nielsen PB, et al. Comparative effectiveness and safety of non–vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2016;353:i3189.
46. Glotzer TV, Ziegler PD. Silent atrial fibrillation as a stroke risk factor and anticoagulation indication. Can J Cardiol 2013;29(7 Suppl):S14-23.
47. Tomson TT, Passman R. Management of device-detected atrial high-rate episodes. Card Electrophysiol Clin 2015;7(3):515-25.
48. Camm AJ, Simantirakis E, Goette A, et al. Atrial high-rate episodes and stroke prevention. Europace 2017;19(2):169-79.
49. Chan AW, Tetzlaff JM, Gatzche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586.
50. Calvert M, Kyte D, Duffy H, et al. Patient-reported outcome (PRO) assessment in clinical trials: a systematic review of guidance for trial protocol writers. PLoS One 2014;9(10):e110216.
51. Calvert M, Blazey J, Altman DG, et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 2013;309(8):814-22.
52. Kirchhof P, Andreassen D, Bosch R, et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet 2012;380(9838):238-46.
53. Wynn GJ, Todd DM, Webber M, et al. The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace 2014;16(7):965-72.
54. Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2007;3:CD006186.
55. Capucci A, Santini L, Padeletti L, et al. Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antithrombotic pacemakers. J Am Coll Cardiol 2005;46(10):1913-20.
56. Botto GL, Padelett L, Santini M, et al. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. J Cardiovasc Electrophysiol 2009;20(3):241-8.